← Leaderboards
Matthew Laughon
Univ Of North Carolina Chapel Hill
$9,477,734
Attributed
$15,716,404
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,656,277 · 7
FDA$3,060,127 · 2
By mechanism
R33$6,819,944 · 1
R01$5,135,355 · 3
UG1$1,068,895 · 1
R61$775,149 · 1
R34$718,621 · 1
K24$612,520 · 1
Top collaborators
- Christoph Hornik5 shared
- Charles Michael Cotten3 shared
- Daniel Gonzalez3 shared
- Jason E. Lang3 shared
- Ryan Thomas Moore3 shared
- Phillip Brian Smith2 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Andrew Olshan$26,924,096
- Tania A. Desrosiers$2,992,500
- Beverly H Koller$30,354,187
- Daniel Gonzalez$6,378,664
- Arash Kheradvar$7,068,840
Others in their field
Top investigators on “Premature Infant”
- Elizabeth A Thom · George Washington University$118,776,833
- Rebecca Gersnoviez Clifton · George Washington University$73,348,985
- Abhik Das · Research Triangle Institute$34,934,786
- Leonardo Trasande · New York University School Of Medicine$26,043,041
- Jack L. Feldman · University Of California Los Angeles$25,357,911
- Alan Thevenet N. Tita · University Of Alabama At Birmingham$24,173,322
Research focus
Premature InfantChildhoodInfantDesignDrug KineticsPharmaceutical PreparationsNeonatalRecording Of Previous EventsClinical TrialsPrematureDoseResearch DesignPreventSiteNational Institute Of Child Health And Human DevelopmentPharmacodynamicsFda ApprovedBronchopulmonary DysplasiaClinical ResearchFundingSafetyLeadPublic HealthNorth Carolina
Grant awards (30)
PRISM$654,096
R01 · FY2025 · HD
North Carolina Clinical Center$339,864
UG1 · FY2025 · HD
PRISM$656,285
R01 · FY2024 · HD
North Carolina Clinical Center$352,458
UG1 · FY2024 · HD
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia$2,186,920
R33 · FY2023 · HL
PRISM$764,847
R01 · FY2023 · HD
North Carolina Clinical Center$376,573
UG1 · FY2023 · HD
Mentorship of Early-Career Clinicians in Bronchopulmonary Dysplasia Drug Therapies$122,504
K24 · FY2023 · HL · contact PI
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia$2,307,686
R33 · FY2022 · HL
Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia$498,118
R01 · FY2022 · FD · contact PI
Mentorship of Early-Career Clinicians in Bronchopulmonary Dysplasia Drug Therapies$122,504
K24 · FY2022 · HL · contact PI
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia$2,325,338
R33 · FY2021 · HL
Mentorship of Early-Career Clinicians in Bronchopulmonary Dysplasia Drug Therapies$122,504
K24 · FY2021 · HL · contact PI
Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia$499,263
R01 · FY2020 · FD · contact PI
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia$362,871
R61 · FY2020 · HL
Mentorship of Early-Career Clinicians in Bronchopulmonary Dysplasia Drug Therapies$122,504
K24 · FY2020 · HL · contact PI
Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia$498,934
R01 · FY2019 · FD · contact PI
Safety of Sildenafil in Premature Infants with Severe Bronchopulmonary Dysplasia$412,278
R61 · FY2019 · HL
Mentorship of Early-Career Clinicians in Bronchopulmonary Dysplasia Drug Therapies$122,504
K24 · FY2019 · HL · contact PI
Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia$498,950
R01 · FY2018 · FD · contact PI
Safety of furosemide in premature infants at risk of bronchopulmonary dysplasia$374,778
R01 · FY2018 · FD · contact PI
Safety of furosemide in premature infants at risk of bronchopulmonary dysplasia$365,227
R01 · FY2017 · FD · contact PI
Echocardiogram to Diagnose Pulmonary Hypertension in Premature Infants$353,201
R34 · FY2016 · HL · contact PI
Safety of furosemide in premature infants at risk of bronchopulmonary dysplasia$324,857
R01 · FY2016 · FD · contact PI
Echocardiogram to Diagnose Pulmonary Hypertension in Premature Infants$365,420
R34 · FY2015 · HL · contact PI
Antimicrobial pharmacokinetics and outcomes in vulnerable infants$66,936
K23 · FY2015 · HD · contact PI
Antimicrobial pharmacokinetics and outcomes in vulnerable infants$119,722
K23 · FY2014 · HD · contact PI
Antimicrobial pharmacokinetics and outcomes in vulnerable infants$133,544
K23 · FY2013 · HD · contact PI
Antimicrobial pharmacokinetics and outcomes in vulnerable infants$133,118
K23 · FY2012 · HD · contact PI
Antimicrobial pharmacokinetics and outcomes in vulnerable infants$132,600
K23 · FY2011 · HD · contact PI